Clinical trials: Papilloma Virus, Human
Cervical Cancer
Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)
Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-based chemotherapy.
- Trial name
- NCT00155766
- Testing
- HPV16 E7 peptide-pulsed autologous DCs
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Human Papilloma Virus
A Multilevel Approach to Increasing HPV Vaccine Initiation Among Adolescents - Part 3
Our project will assess the feasibility and estimate preliminary efficacy of a multilevel intervention to improve HPV vaccine series initiation among adolescents in Medicaid and CHIP.
- Trial name
- NCT04208269
- Testing
- postcard campaign, Health Information Technology system
- Where
- United States
- Volunteers
- 5,663 people, healthy volunteers welcome
- Sponsor
- University of Florida
Anal Cancer, Cervical Cancer
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients…
- Conditions
- Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00019110
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
- Where
- 6 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 1
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
This randomized phase II trial is studying green tea extract to see how well it works compared to a placebo in preventing cervical cancer in patients with human papillomavirus and low-grade cervical intraepithelial neoplasia.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 1, Human Papilloma Virus Infection
- Trial name
- NCT00303823
- Testing
- defined green tea catechin extract, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions
Cervical cancer is the most frequent neoplasm and the third in mortality rate of the malignancies in women in the world. It results in about 200,000 women dying of cervical cancer each year worldwide.
- Trial name
- NCT00154583
- Where
- Taiwan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT01932697
- Testing
- Docetaxel, Hyperfractionation, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Human Papillomavirus, HIV-1 Infection
A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years
The purpose of this study is to determine sustained immunogenicity of the quadrivalent vaccine 'Gardasil', 48 months after initial vaccination, among HIV-1 infected boys and girls age 9-14 years.
- Trial name
- NCT01446718
- Testing
- Gardasil vaccine
- Volunteers
- 179 people
- Sponsor
- Kenya Medical Research Institute
Recurrent Respiratory Papillomatosis, Papillomavirus Infection
Zopa Retreatment and Vector Shedding in Adults With RRP
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP).
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
- Trial name
- NCT06538480
- Testing
- Zopapogene imadenovec (Zopa)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Precigen, Inc
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean…
- Trial name
- ADS (NCT02280642)
- Testing
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late
- Where
- 3 sites in United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Duke University
Human Papilloma Virus
Carrageenan for the Prevention of Oral HPV Infection
This is a placebo-controlled, triple-blind randomized clinical trial (RCT) designed to evaluate the feasibility of conducting a larger multicentric RCT investigating the effect of a Carrageenan mouthwash on oral HPV infection.
- Trial name
- NCT05746988
- Testing
- Mouthwash gargling
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- McGill University
Infections, Papillomavirus
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
Human Papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GlaxoSmithKline (GSK) Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types…
- Trial name
- NCT00541970
- Testing
- Cervarix
- Where
- 25 sites in Canada, Germany
- Volunteers
- 961 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, DNA Methylation
Cervical Cytology DNA Methylation for Cervical Cancer Screening
Cervical cancer represents one of the foremost causes of cancer-related morbidity and mortality among women worldwide. Given the current limitations, such as the low specificity of human papillomavirus (HPV) testing and the…
- Conditions
- Cervical Cancer, DNA Methylation, Cytology, Human Papillomavirus Infection
- Trial name
- NCT06557954
- Testing
- human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)
- Where
- China
- Volunteers
- 30,000 people
- Sponsor
- Lei Li
Human Papilloma Virus Infection
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County.
- Trial name
- NCT02067507
- Testing
- Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems
- Where
- 2 sites in United States
- Volunteers
- 53,414 people
- Sponsor
- University of California, Los Angeles
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer.
- Trial name
- NCT01221753
- Testing
- docetaxel, cisplatin, 5-FU
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Infections, Papillomavirus
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00456807
- Testing
- Cervarix TM
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
High-grade Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer
Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm
The purpose is to evaluate whether implementation of primary human papillomavirus (HPV) screening in the screening programme for cervical cancer improves the programme in terms of better cancer protection and better cost…
- Trial name
- NCT01511328
- Testing
- HPV testing
- Where
- Sweden
- Volunteers
- 270,000 people
- Sponsor
- Karolinska Institutet
Warts
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.
- Trial name
- NCT04399577
- Testing
- Candida antigen
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Zagazig University
Human Papilloma Virus Infection, Cervical Intraepithelial Neoplasia Grade 2/3
The HPV Self-test as a Test of Cure in Madagascar
The purpose of this study is to find out whether Self-HPV may be an accurate method for the follow-up of women with a history of HPV infection.
- Trial name
- NCT02811367
- Testing
- HPV test
- Where
- Madagascar
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Human Papillomavirus-Related Cervical Carcinoma
Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida
Human Papilloma Virus (HPV) is a cause of cervical cancer in women. This study is being done to identify sites for cervical cancer screening and education regarding HPV vaccination outside of the traditional settings of primary…
- Trial name
- NCT06607874
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.